BridgeBio Oncology Therapeutics (BBOT) Stock Forecast: StockMap's 2-Week Call
BBOT stock forecast: StockMap's model leans Underperform on BridgeBio Oncology Therapeutics for the two weeks after the Nov 19 close, toward BBOT trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 6 of 6 two-week windows on BBOT since Aug 21; by chance, a call on the same dates was right 59% of the time.
BridgeBio Oncology Therapeutics last closed at $1.86, +3.33% on the session.
Against the IVW growth benchmark the position is +5.66% over the forecast window.
BridgeBio Oncology Therapeutics' market cap is $149.68M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).
Where BBOT sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
49 daily calls for BBOT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks BridgeBio Oncology Therapeutics in the 18th percentile on return on equity, where 100 is best.
BridgeBio Oncology Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks BridgeBio Oncology Therapeutics as the 250th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite BridgeBio Oncology Therapeutics ranks 179th of 394 in the group, against a group median of -0.27.